Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model

Strahlentherapie und Onkologie

Volumn 189, Issue 11, 2013, Pages 957-966

  Blattmann, C ^a,b   Thiemann, M ^c   Stenzinger, A ^d   Christmann, A ^c   Roth, E ^b   Ehemann, V ^d   Debus, J ^c   Kulozik, A E ^b   Weichert, W ^d   Huber, P E ^c   Oertel, S ^c   Abdollahi, A ^c,e  

^a Pädiatrie 5   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD95; Histone deacetylase inhibition; Osteosarcoma; Radiotherapy; Suberoylanilide hydroxamic acid

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; PROTEIN P21; PROTEIN P53; VORINOSTAT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NECROSIS; NONHUMAN; OSTEOSARCOMA; RADIOSENSITIZATION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, SCID; OSTEOSARCOMA; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84887215017     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0372-8     Document Type: Article

References (39)

1. Belka C, Marini P, Budach W et al (1998) Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiat Res 149:588-595
2. Bellarosa D, Bressan A, Bigioni M et al (2012) SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol41:1486-1494
3. Bielack S, Jürgens H, Jundt G et al (2009) Osteosarcoma: the COSS experience. Cancer Treat Res 152:289-308
4. Bielack SS, Carrle D, Hardes J et al (2008) Bone tumors in adolescents and young adults. Curr Treat Options Oncol 9:67-80
5. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790
6. Blattmann C, Oertel S, Ehemann V et al (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237-245
7. Blattmann C, Oertel S, Thiemann M et al (2012) Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. Strahlenther Onkol 188:168-176
8. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15:3970-3977
9. Bridges KA, Hirai H, Buser CA et al (2011) MK-1775, a novel wee1 kinase inhibitor radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17:5638-5648
10. Dickinson M, Johnstone RW, Prince HM (2012) Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 28(Suppl 1):S3-S20
11. Robert C, Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116:87-129
12. Eckner R (2012) p53-dependent growth arrest and induction of p21: a critical role for PCAF-mediated histone acetylation. Cell Cycle 11:2591-2592
13. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280:145-153
14. Entin-Meer M, Yang X, Vandenburg SR et al (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9:82-88
15. Folkvord S, Ree AH, Furre T et al (2009) Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 74:546-552
16. Greve B, Sheikh-Mounessi F, Kemper B et al (2012) Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma. Strahlenther Onkol 188(11):1038-1047
17. Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 125:280-233
18. Fuchs EJ, McKenna KA, Bedi A (1997) p53-dependent DNA-damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32?. Cancer Res 57:2550-2554
19. Hundsdoerfer P, Albrecht M, Rühl U et al (2009) Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma. Eur J Cancer 45:2447-2451
20. Johnstone RW, Licht JD (2003) Histone seacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-18
21. Kawano T, Akiyama M, Agawa-Ohta M et al (2010) Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation- phosphorylation. Int J Oncol 37:787-795
22. Koshkina NV, Rao-Bindal K, Kleinermann ES (2011) Effect of the HDAC inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metafase. Cancer 117:3457-3467
23. Langenbacher M, Abdel-Jalil RJ, Voelter W et al (2013) In vitro hypoxic cytotoxicity and hypoxic radiosensitization: efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine. Strahlenther Onkol 189:246-255
24. Ma X, Ezzeldin HH, Diaso RB (2009) Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69:1911-1934
25. Mottet D, Castronovo V (2010) Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets 10:898-913
26. Müller M, Wilder S, Bannasch D et al (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033-2045
27. Munshi A, Kurland JF, Nishikawa T et al (2005) Histone deacetylase inhibitors radiosensitize human melanoma by suppressing DNA repair activity. Clin Cancer Res 11:4912-4922
28. New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6:637-656
29. Oertel S, Thiemann M, Richter K et al (2011) Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol 20:119
30. Robert C, Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116:87-129
31. Romano JW, Ehrhart JC, Duthu A et al (1989) Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 4(12):1483-1488
32. Schuchmann M, Schulze-Bergkamen H, Fleischer B et al (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15:227-230
33. Shabason JE, Tofilon PJ, Camphausen K (2011) Grand rounds at the national institutes of health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15:2735-2744
34. Tamura T, Aoyama H, Saya H et al (1995) Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11:1939-1946
35. Thayanithy V, Park C, Sarver AL et al (2012) Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One 7:e43720
36. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604
37. Watanabe K, Okamoto K, Yonehara S (2005) Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12:10-18
38. Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I et al (2011) Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 15:17:3956-3968
39. Zhao Y, Lu S, Wu L et al (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21[Waf1/Cip1]. Mol Cell Biol 26:2782-2790